Physical Activity and Trajectory of Cognitive Change in Older Persons: Mayo Clinic Study of Aging.


Journal

Journal of Alzheimer's disease : JAD
ISSN: 1875-8908
Titre abrégé: J Alzheimers Dis
Pays: Netherlands
ID NLM: 9814863

Informations de publication

Date de publication:
2021
Historique:
pubmed: 21 11 2020
medline: 28 9 2021
entrez: 20 11 2020
Statut: ppublish

Résumé

Little is known about the association between physical activity (PA) and cognitive trajectories in older adults. To examine the association between PA and change in memory, language, attention, visuospatial skills, and global cognition, and a potential impact of sex or Apolipoprotein E (APOE) ɛ4 status. Longitudinal study derived from the population-based Mayo Clinic Study of Aging, including 2,060 cognitively unimpaired males and females aged ≥70 years. Engagement in midlife (ages 50-65) and late-life (last year) PA was assessed using a questionnaire. Neuropsychological testing was done every 15 months (mean follow-up 5.8 years). We ran linear mixed-effect models to examine whether mid- or late-life PA at three intensities (mild, moderate, vigorous) was associated with cognitive z-scores. Light intensity midlife PA was associated with less decline in memory function compared to the no-PA reference group (time x light PA; estimate [standard error] 0.047 [0.016], p = 0.004). Vigorous late-life PA was associated with less decline in language (0.033 [0.015], p = 0.030), attention (0.032 [0.017], p = 0.050), and global cognition (0.039 [0.016], p = 0.012). Females who were physically inactive in midlife experienced more pronounced cognitive decline than females physically active in midlife and males regardless of PA (p-values for time interaction terms with midlife PA levels and sex were all p < 0.05 for global cognition). APOE ɛ4 carriership did not moderate the association between PA and cognition. Engaging in PA, particularly of vigorous intensity in late-life, was associated with less pronounced decline in global and domain-specific cognition. This association may differ by sex.

Sections du résumé

BACKGROUND
Little is known about the association between physical activity (PA) and cognitive trajectories in older adults.
OBJECTIVE
To examine the association between PA and change in memory, language, attention, visuospatial skills, and global cognition, and a potential impact of sex or Apolipoprotein E (APOE) ɛ4 status.
METHODS
Longitudinal study derived from the population-based Mayo Clinic Study of Aging, including 2,060 cognitively unimpaired males and females aged ≥70 years. Engagement in midlife (ages 50-65) and late-life (last year) PA was assessed using a questionnaire. Neuropsychological testing was done every 15 months (mean follow-up 5.8 years). We ran linear mixed-effect models to examine whether mid- or late-life PA at three intensities (mild, moderate, vigorous) was associated with cognitive z-scores.
RESULTS
Light intensity midlife PA was associated with less decline in memory function compared to the no-PA reference group (time x light PA; estimate [standard error] 0.047 [0.016], p = 0.004). Vigorous late-life PA was associated with less decline in language (0.033 [0.015], p = 0.030), attention (0.032 [0.017], p = 0.050), and global cognition (0.039 [0.016], p = 0.012). Females who were physically inactive in midlife experienced more pronounced cognitive decline than females physically active in midlife and males regardless of PA (p-values for time interaction terms with midlife PA levels and sex were all p < 0.05 for global cognition). APOE ɛ4 carriership did not moderate the association between PA and cognition.
CONCLUSION
Engaging in PA, particularly of vigorous intensity in late-life, was associated with less pronounced decline in global and domain-specific cognition. This association may differ by sex.

Identifiants

pubmed: 33216032
pii: JAD200959
doi: 10.3233/JAD-200959
pmc: PMC7839815
mid: NIHMS1659200
doi:

Substances chimiques

Apolipoprotein E4 0

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

377-388

Subventions

Organisme : NIA NIH HHS
ID : R01 AG034676
Pays : United States
Organisme : NIA NIH HHS
ID : P50 AG016574
Pays : United States
Organisme : NIA NIH HHS
ID : R33 AG058738
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG057708
Pays : United States
Organisme : NIA NIH HHS
ID : U01 AG006786
Pays : United States

Références

J Int Neuropsychol Soc. 2015 Nov;21(10):816-30
pubmed: 26581793
Vital Health Stat 10. 1986 Sep;(160):i-iv, 1-182
pubmed: 3811243
Med Sci Sports Exerc. 2017 Jan;49(1):47-53
pubmed: 27580146
Neuroepidemiology. 2008;30(1):58-69
pubmed: 18259084
J Alzheimers Dis. 2019;71(1):109-118
pubmed: 31356211
Arch Neurol. 2010 Jan;67(1):80-6
pubmed: 20065133
J Gerontol A Biol Sci Med Sci. 2017 Jun 01;72(6):789-795
pubmed: 27422439
Arch Neurol. 1991 Jul;48(7):725-8
pubmed: 1859300
J Am Geriatr Soc. 2016 Dec;64(12):2479-2486
pubmed: 27801933
Int J Geriatr Psychiatry. 2018 Jan;33(1):21-30
pubmed: 28094873
Neurology. 2016 May 17;86(20):1897-903
pubmed: 27009261
Lancet Neurol. 2005 Nov;4(11):705-11
pubmed: 16239176
Alzheimers Dement. 2015 Apr;11(4):434-443.e6
pubmed: 24721528
J Lipid Res. 1990 Mar;31(3):545-8
pubmed: 2341813
Am J Geriatr Psychiatry. 2021 Feb;29(2):141-143
pubmed: 32873497
Brain Plast. 2018 Dec 12;4(1):53-63
pubmed: 30564546
PLoS One. 2019 Jan 10;14(1):e0210036
pubmed: 30629631
J Aging Phys Act. 2018 Jul 1;26(3):353-362
pubmed: 28952854
FASEB J. 2020 Sep;34(9):11329-11336
pubmed: 32761860
Neuropsychology. 2016 Jan;30(1):6-17
pubmed: 26710092
J Intern Med. 2004 Sep;256(3):183-94
pubmed: 15324362
Medicine (Baltimore). 2020 Jul 31;99(31):e20105
pubmed: 32756073
Front Neuroendocrinol. 2017 Jul;46:71-85
pubmed: 28442274
Med Sci Sports Exerc. 2001 May;33(5):772-7
pubmed: 11323547
Am J Epidemiol. 1985 Apr;121(4):570-9
pubmed: 4014146
J Am Geriatr Soc. 2015 Dec;63(12):2447-2454
pubmed: 26691697
Curr Alzheimer Res. 2019;16(4):316-332
pubmed: 30819077
J Exerc Rehabil. 2018 Aug 24;14(4):586-591
pubmed: 30276178
Neuroepidemiology. 2009;33(1):47-54
pubmed: 19365142
Alzheimer Dis Assoc Disord. 2014 Jan-Mar;28(1):50-7
pubmed: 23739296
Ageing Res Rev. 2020 Dec;64:101173
pubmed: 32961338
J Clin Exp Neuropsychol. 1998 Apr;20(2):194-200
pubmed: 9777473
Science. 1993 Aug 13;261(5123):921-3
pubmed: 8346443
BMJ. 2017 Jun 22;357:j2709
pubmed: 28642251
J Chronic Dis. 1987;40(5):373-83
pubmed: 3558716
Ann Behav Med. 2018 Feb 5;52(2):175-185
pubmed: 29538632
Neuroimage. 2016 May 1;131:142-54
pubmed: 26545456
J Clin Med. 2019 Jun 21;8(6):
pubmed: 31234307
Alzheimers Dement (N Y). 2018 Jul 14;4:263-271
pubmed: 30090846
J Sci Med Sport. 2018 May;21(5):489-494
pubmed: 28919495
J Am Geriatr Soc. 2013 Nov;61(11):1927-31
pubmed: 24219194
J Intern Med. 2004 Sep;256(3):240-6
pubmed: 15324367
Neurology. 1993 Aug;43(8):1467-72
pubmed: 8350998
Neurology. 1993 Nov;43(11):2412-4
pubmed: 8232972
Exp Gerontol. 2017 May;91:104-109
pubmed: 28263868
Eur J Epidemiol. 2016 Mar;31(3):267-74
pubmed: 26857126
Gerontology. 2018;64(4):361-372
pubmed: 29402782
Age Ageing. 2019 Mar 1;48(2):241-246
pubmed: 30615048
BMJ. 2018 May 16;361:k1675
pubmed: 29769247

Auteurs

Janina Krell-Roesch (J)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.

Jeremy A Syrjanen (JA)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Jelena Bezold (J)

Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.

Sandra Trautwein (S)

Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.

Bettina Barisch-Fritz (B)

Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.

Klaus Boes (K)

Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.

Alexander Woll (A)

Institute of Sports and Sports Science, Karlsruhe Institute of Technology, Karlsruhe, Germany.

Erica Forzani (E)

Biodesign Institute, Arizona State University, Tempe, AZ, USA.

Walter K Kremers (WK)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Mary M Machulda (MM)

Department of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.

Michelle M Mielke (MM)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Department of Neurology, Mayo Clinic, Rochester, MN, USA.

David S Knopman (DS)

Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Ronald C Petersen (RC)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.
Department of Neurology, Mayo Clinic, Rochester, MN, USA.

Maria Vassilaki (M)

Department of Health Sciences Research, Mayo Clinic, Rochester, MN, USA.

Yonas E Geda (YE)

Biodesign Institute, Arizona State University, Tempe, AZ, USA.
Department of Neurology, Barrow Neurological Institute, Phoenix, AZ, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH